• Users Online: 369
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2011  |  Volume : 2  |  Issue : 3  |  Page : 248-253

Expression and prognostic value of the drug resistance proteins Pgp-170, MRP2, MMR3, and MRP5 in leukemia


Biology Department, College of Science and King Fahd Medical Research Center, King Abdulaziz University P.O. Box 80216, Jeddah 21589, Kingdom of Saudi Arabia

Correspondence Address:
Ph.D. Sufian M ElAssouli
Biology Department, College of Science and King Fahd Medical Research Center, King Abdulaziz University P.O. Box 80216, Jeddah 21589
Kingdom of Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Multidrug resistance mediated by the transporter proteins P-glycoprotein (Pgp-170) and multidrug resistance associated proteins (MRP1-9) is one of the mechanisms that contribute to the failure of chemotherapy in patients with different malignancies. The objective of the present study was to investigate the expression of the drug resistance proteins Pgp-170, MRP2, MRP3 and MRP5 (DRPs) in leukemic patients and to assess their possible association with the clinical features. These proteins were determined using immunocytochemistry and flow cytometry in 88 blood samples from 51 patients. Immunocytochemically, the overall expression of Pgp-170, MRP2, MRP3, and MRP5 in the untreated, remission, and relapsed samples was 8.7%, 13.2%, and 48.2%, respectively. In acute lymphocytic leukemia (ALL), DRPs were detected in 0/4 untreated 1/17 remission, and 7/12 relapsed samples. In acute myelocytic leukemia (AML), DRPs were detected in 2/9 untreated 2/8 remission, and 4/12 untreated relapsed samples. In chronic myelocytic leukemia (CML), DRPs were not detected in the untreated (n=5) or remission (n=1) samples. In chronic lymphocytic leukemia (CLL), DRPs were not detected in the untreated samples (n=3), but they were detected in 1/2 remission and 2/3 of relapsed samples. In multiple myelomas (MM), the 2 untreated samples were negative for DRPs, while 1/10 remission samples was positive. Analysis of 58 blood-samples using flow-cytometry, detected DRPs in 4%, 15%, and 9% of the untreated (n=19), remission (n=18), and relapsed (n=21) samples, respectively. The chi-square test showed that there were no significant associations between immunocytostaining and flow-cytometry or between DRP expression and patients age or sex.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1102    
    Printed43    
    Emailed0    
    PDF Downloaded87    
    Comments [Add]    

Recommend this journal